Subscribe

What are you looking for?

Main Menu

明報新聞網

和黃醫藥：凡瑞格拉替尼上市申請獲受理並被納入優先審評

Future Wealths
Future Wealths
29 12 月, 2025
One Min Read
5 Views
0 Comments
和黃醫藥（0013）宣佈凡瑞格拉替尼（fanregratinib ，HMPL-453）用於既往接受過系統性治療，且具有成纖維細胞生長因子受體（FGFR）2融合或重排的晚期、轉移性或不可手術切除的肝內膽管癌（ICC）成人患者的新藥上市申請已獲中國國家藥品監督管理局受理，並獲納入優先審評。

原文: https://finance.mingpao.com/fin/instantf/20251229/1766999521474/%e5%92%8c%e9%bb%83%e9%86%ab%e8%97%a5-%e5%87%a1%e7%91%9e%e6%a0%bc%e6%8b%89%e6%9b%bf%e5%b0%bc%e4%b8%8a%e5%b8%82%e7%94%b3%e8%ab%8b%e7%8d%b2%e5%8f%97%e7%90%86%e4%b8%a6%e8%a2%ab%e7%b4%8d%e5%85%a5%e5%84%aa%e5%85%88%e5%af%a9%e8%a9%95

Last Update: 29 12 月, 2025

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept